Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy
- PMID: 33097308
- DOI: 10.1016/j.jhep.2020.07.013
Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy
Abstract
Hepatic encephalopathy (HE) is a frequent and serious complication of both chronic liver disease and acute liver failure. HE manifests as a wide spectrum of neuropsychiatric abnormalities, from subclinical changes (mild cognitive impairment) to marked disorientation, confusion and coma. The clinical and economic burden of HE is considerable, and it contributes greatly to impaired quality of life, morbidity and mortality. This review will critically discuss the latest classification of HE, as well as the pathogenesis and pathophysiological pathways underlying the neurological decline in patients with end-stage liver disease. In addition, management strategies, diagnostic approaches, currently available therapeutic options and novel treatment strategies are discussed.
Keywords: Ammonia; Diagnosis; Hepatic encephalopathy; Management; Pathogenesis; Pathophysiology; Treatments.
Crown Copyright © 2020. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflicts of interest Christopher Rose has research collaborations with Mallinckrodt and Neuractas and is an advisor for Axcella, Horizon Therapeutics, Lupin Pharma Canada, Morphocell Technologies, Neuractas, Sana Biotechnologies and Thoeris. Jasmohan Bajaj has research collaborations with Grifols, Valeant and Mallinckrodt. Sara Montagnese is an advisor for Umecrine, Meddey and Versantis and her group has received research funds from Alfasigma, Ogilvie, Falk and Merz. Simon Taylor-Robinson has had previous research collaborations with Merz GmbH (Frankfurt, Germany) and has spoken at Merz and Norgine-sponsored symposia. Rajiv Jalan has research collaborations with Yaqrit and Takeda. Rajiv Jalan is the inventor of OPA, which has been patented by UCL and licensed to Mallinckrodt. He is also the founder of Yaqrit Ltd, a spin out company from University College London. He is also a Founder of Thoeris Ltd. Other authors have no conflicts to declare. Please refer to the accompanying ICMJE disclosure forms for further details.
Similar articles
-
Hepatic encephalopathy: a critical current review.Hepatol Int. 2018 Feb;12(Suppl 1):135-147. doi: 10.1007/s12072-017-9812-3. Epub 2017 Aug 2. Hepatol Int. 2018. PMID: 28770516 Free PMC article. Review.
-
Hepatic encephalopathy: an updated approach from pathogenesis to treatment.Med Sci Monit. 2011 Feb;17(2):RA53-63. doi: 10.12659/msm.881387. Med Sci Monit. 2011. PMID: 21278704 Free PMC article. Review.
-
Neurocritical Care Management of Hepatic Encephalopathy and Coma in Liver Failure.Semin Respir Crit Care Med. 2018 Oct;39(5):523-537. doi: 10.1055/s-0038-1672180. Epub 2018 Nov 28. Semin Respir Crit Care Med. 2018. PMID: 30485883 Review.
-
Management of hepatic encephalopathy in patients with cirrhosis.Best Pract Res Clin Gastroenterol. 2007;21(1):95-110. doi: 10.1016/j.bpg.2006.07.009. Best Pract Res Clin Gastroenterol. 2007. PMID: 17223499 Review.
-
Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy.Ann Hepatol. 2011 Jun;10 Suppl 2:S36-9. Ann Hepatol. 2011. PMID: 22228879 Review.
Cited by
-
Hypokalaemia - an active contributor to hepatic encephalopathy?Metab Brain Dis. 2023 Jun;38(5):1765-1768. doi: 10.1007/s11011-022-01096-0. Epub 2022 Nov 3. Metab Brain Dis. 2023. PMID: 36326977
-
Bibliometrics and knowledge mapping of the pathogenesis of hepatic encephalopathy in patients with liver cirrhosis.Heliyon. 2024 Jul 16;10(15):e34330. doi: 10.1016/j.heliyon.2024.e34330. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39145014 Free PMC article.
-
The Value of Ammonia as a Biomarker in Patients with Cirrhosis.Semin Liver Dis. 2024 Aug;44(3):356-368. doi: 10.1055/a-2378-8942. Epub 2024 Aug 2. Semin Liver Dis. 2024. PMID: 39095029 Free PMC article. Review.
-
The Role of Gut Microbiota in Some Liver Diseases: From an Immunological Perspective.Front Immunol. 2022 Jul 13;13:923599. doi: 10.3389/fimmu.2022.923599. eCollection 2022. Front Immunol. 2022. PMID: 35911738 Free PMC article. Review.
-
Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota.Front Microbiol. 2023 Mar 24;14:1091167. doi: 10.3389/fmicb.2023.1091167. eCollection 2023. Front Microbiol. 2023. PMID: 37032856 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical